Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Opioid Substitution Therapy in HCV Patients

J Infect Dis; ePub 2017 Dec 26; Stepanova, et al

Receiving interferon-free regimens led to patient-reported outcome (PRO) improvement during treatment for hepatitis C virus (HCV) and after SVR regardless of opioid substitution therapy (OST) status, a recent study found. Patients were enrolled in phase 3 clinical trials of sofosbuvir and completed 4 PRO instruments: SF-36V2, FACIT-F, CLDQ-HCV, and WPAI-HCV before, during, and post-treatment. 8,450 HCV individuals were included; 407 (4.8%) were on OST. Researchers found:

  • At baseline, OST participants had significantly lower PRO scores.
  • By treatment completion, those receiving IFN+RBV+SOF experienced significant decreases in PROs regardless of OST use.
  • Those receiving IFN-free RBV+ regimens had significant but smaller PRO decreases; similar in OST and non-OST.
  • Those treated with IFN/RBV-free regimens showed improvement in nearly all PROs during treatment which was more pronounced in OST individuals.

Citation:

Stepanova M, Thompson A, Doyle J, Younossi I, de Avila L, Younossi ZM. Hepatitis C patients receiving opioid substitution therapy experience improvement in patient-reported outcomes following treatment with interferon-free regimens. [Published online ahead of print December 26, 2017]. J Infect Dis. doi:10.1093/infdis/jix681.

This Week's Must Reads

CDC Metric for Measuring & Comparing Antibiotic Use, Clin Infect Dis; ePub 2018 Feb 2; van Santen, et al

Racial Disparities in Lifetime Risk of Chlamydia, Clin Infect Dis; ePub 2018 Feb 6; Chambers, et al

Regional Spread of CRE Among Healthcare Facilities, Clin Infect Dis; ePub 2018 Feb 3; Ray, et al

Daily vs Nondaily Oral PrEP in At-Risk Groups, Clin Infect Dis; ePub 2018 Feb 6; Grant, et al

HCV Treatment as Prevention in PWIDs, Lancet; 2018 Feb; Zelenev, Li, et al

Must Reads in Hepatitis

HCV Treatment as Prevention in PWIDs, Lancet; 2018 Feb; Zelenev, Li, et al

Microbial Translocation & Immune Activation in HIV and HCV, J Infect Dis; ePub 2018 Jan 3; Reid, Ma, et al

Opioid Substitution Therapy in HCV Patients, J Infect Dis; ePub 2017 Dec 26; Stepanova, et al

Improving Access to HCV Infection Treatment, Open Forum Infect Dis; ePub 2017 Dec 9; Collins, et al

HbA1c Improvement After HCV Clearance in HIV?, J Infect Dis; ePub 2017 Nov 18; Chaudhury, et al